unknown
Stage
About
GABA Therapeutics is a mid-stage biotechnology company developing novel therapies for psychiatric and neurological disorders; its lead candidate GRX-917 is a deuterated analog of an approved anxiety medication designed to provide benzodiazepine-like efficacy with reduced addiction risk by increasing endogenous neurosteroids and inhibiting NLRP3-driven inflammation.
Explore GABA Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.